Basilea Pharmaceutica 启动了抗真菌药物 fosmanogepix 治疗念珠菌血症和侵袭性念珠菌病的 3 期试验。 Basilea Pharmaceutica launches phase 3 trial for antifungal drug fosmanogepix in candidemia and invasive candidiasis.

Basilea Pharmaceutica已经启动其抗真菌药物fosmanogepix的第三期临床试验,旨在治疗患有候群病和侵袭性候群病的成年患者,这是由Candida酵母引起的严重感染. Basilea Pharmaceutica has launched a phase 3 clinical trial for its antifungal drug, fosmanogepix, aimed at treating adult patients with candidemia and invasive candidiasis, serious infections caused by Candida yeast. Fosmanogepix 已获得多个 FDA 指定，在一项全球随机双盲研究中与标准治疗卡泊芬净进行了评估。 Fosmanogepix, which has received multiple FDA designations, is evaluated against standard treatment caspofungin in a global, randomized, double-blind study. 这项试验旨在确定其作为一流治疗的有效性和安全性. This trial seeks to establish its efficacy and safety as a first-in-class treatment.